Ontology highlight
ABSTRACT:
SUBMITTER: Xiong W
PROVIDER: S-EPMC3383530 | biostudies-literature | 2011 Oct
REPOSITORIES: biostudies-literature
Xiong Wen W Lahita Robert G RG
Therapeutic advances in musculoskeletal disease 20111001 5
There are many new therapeutic directions for the disease systemic lupus erythematosus (SLE). Despite this, the US Food and Drug Administration (FDA) has approved only one biological agent and it involves B cells, now thought to play a significant role in the pathogenesis of SLE. The name of the drug is belimumab, which is an agent that removes the B-cell cytokine called B lymphocyte stimulation factor (BLyS). Rituximab did not achieve its primary endpoints, even though the consensus is that it ...[more]